Ticker LaunchUplisting · KMPH
Zevra Therapeutics, Inc.
Formerly KEMPHARM, INC; KEMPHARM INC
Zevra Therapeutics, Inc. (KMPH), already reporting to the SEC, moved up to a national exchange on Jan 11, 2021 with an offering at $6.50 per share. Roth Capital was lead-left underwriter. Cooley advised the company and Ellenoff Grossman & Schole advised the underwriters.
Zevra Therapeutics, Inc. is a specialty pharmaceutical company that develops prodrugs using its Ligand Activated Therapy technology. Its pipeline targets ADHD, stimulant use disorder and idiopathic hypersomnia, with co-lead candidates KP415 and KP484, both based on a d-methylphenidate prodrug, for ADHD.
- Status
- Uplisting
- Ticker
- KMPH
- Listed
- Jan 11, 2021
- Price
- $6.50
- Market cap at IPO price
- $79.5M
- First filed
- Mar 11, 2015
- Underwriters
- Roth Capital
- Company counsel
- Cooley
- Underwriters' counsel
- Ellenoff Grossman & Schole
- Sector
- Biotech & pharma
- Country / state
- MA
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Mar 11, 2015
- Latest amendment Jan 5, 2021
- Final prospectus (424B4) Jan 11, 2021
- All filings on EDGAR CIK 1434647
Other Biotech & pharma uplistings in 2021
- Evotec SEEVO · Nov 5, 2021 · $435M
- Zivo Bioscience, Inc.ZIVO · Jun 1, 2021 · $13.8M
- Nexentis Technologies Inc.SVFD · May 17, 2021 · $12M
- Protagenic Therapeutics, Inc.\newPTIX · Apr 28, 2021 · $13.2M
- GT Biopharma, Inc.GTBP · Feb 12, 2021 · $23.6M
- Lexaria Bioscience Corp.LEXX · Jan 14, 2021 · $9.6M